Biotech: Down for the Count

Stirling, UK-Scotia became the first public UK biotechnology company to seek protection from creditors after the European Medicines Evaluation Agency rejected Foscan (temoporfin), the anticancer agent on which its fortunes were pinned.

Related Content:

Pharmaceutical Executive-03-01-2001

Research: New Horizons

The Challenge of Prescription Drug Pricing

Earnings: Tough Times Ahead